Once registered, you can:

  • - Read additional free articles each month
  • - Comment on articles and featured creative work
  • - Get our curated newsletters delivered to your inbox

By registering you agree to our privacy policy, terms & conditions and to receive occasional emails from Ad Age. You may unsubscribe at any time.

Are you a print subscriber? Activate your account.

Femstat 3 goes OTC

Published on .

The Food & Drug Administration has granted over-the-counter approval to Femstat 3, a treatment for vaginal yeast infections. The product is a joint venture of Procter & Gamble Co. and Roche Holding. Its claimed advantage is that it works in three days rather than the seven days of similar products, such as Johnson & Johnson's Monistat 7, the market leader. Femstat 3 will reach retail stores by spring and will receive ad support through Leo Burnett USA, Chicago.

Most Popular
In this article: